文献速递临床试验与 GCP真实世界研究与卫生经济流行病学与生物统计

SCHEMA随机对照试验中针对安全护理医院人际艺术心理治疗评估的统计与健康经济分析计划

Statistical and health economic analysis plan for a secure care hospital evaluation of manualised (interpersonal) art-psychotherapy: the SCHEMA randomized controlled trial.
PubMed 文献 · Trials · 2025-07-01

SCHEMA试验为多中心、双臂、平行组、单盲、个体随机对照试验,纳入150名NHS安全护理机构中边缘至轻中度智力障碍成人,比较人际艺术心理治疗与常规护理对攻击行为频率/严重度及精神症状相关痛苦的影响。本文描述该试验的统计与健康经济分析计划,计划在数据库锁定及揭盲前制定。

要点

  • 主要结局为随机化后19周改良外显攻击量表(MOAS)评估的攻击行为频率/严重度,采用线性混合效应模型分析。
  • 次要结局包括19至38周每周MOAS评分变化及基线、19周、38周简明症状量表阳性症状痛苦指数。
  • 健康经济分析基于38周增量成本每质量调整生命年,收集自报及代理报告的EQ-5D-3L和ReQoL-10。

核心结论

  • 本文详述SCHEMA试验的计划分析,并讨论招募挑战、样本量影响及效应量假设。

研究设计与样本

  • 多中心、双臂、平行组、单盲、个体随机对照试验,纳入150名NHS安全护理机构中边缘至轻中度智力障碍成人。

主要发现

  • 主要结局为随机化后19周MOAS评估的攻击行为频率/严重度,采用线性混合效应模型,校正基线MOAS并按性别和精神病诊断分层。
  • 利用19至38周每周MOAS评分评估攻击行为变化。
  • 采用简明症状量表阳性症状痛苦指数在基线、19周和38周评估精神症状相关痛苦。
  • 采用自报和代理报告的EQ-5D三水平(EQ-5D-3L)及Recovering Quality of Life 10条目量表在基线、19周和38周评估健康相关生活质量,后者用于估计ReQoL效用指数。
  • 基于安全护理记录收集资源使用,估计19周和38周的干预及医疗成本。

关键数值与推荐

  • 健康相关生活质量和成本数据将用于基于38周增量成本每质量调整生命年的成本效果分析。
  • 自报EQ-5D-3L采用针对智力障碍人群的改编版本收集。

局限性

  • 本文讨论招募挑战、样本量影响及效应量假设。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The SCHEMA trial evaluates whether interpersonal art psychotherapy reduces the frequency/severity of aggressive incidents or patient distress associated with psychiatric symptoms, compared to usual care. OBJECTIVE: To describe the statistical and health economic analysis plan. METHODS: A multicentre, two-arm, parallel-group, single blind individually randomised controlled trial with 150 adults within NHS secure care who have borderline to mild/moderate intellectual disability. The primary outcome is the frequency/severity of aggressive behaviour, measured on the Modified Overt Aggression Scale (MOAS) 19 weeks post-randomisation, analysed using a linear mixed-effect model, adjusted for baseline MOAS and stratification by gender and psychosis diagnosis. Changes in aggressive behaviour will be evaluated using weekly MOAS scores between 19 and 38 weeks. Patient distress relating to psychiatric symptoms will be assessed using the Brief Symptom Inventory Positive Symptom Distress Index across baseline, 19, and 38 weeks. Health-related quality-of-life will be assessed using self- and proxy-reported EQ-5D three-level (EQ-5D-3L) and Recovering Quality of Life 10-item measures, the latter to estimate the ReQoL Utility Index, across baseline, 19, and 38 weeks. The self-reported EQ-5D-3L is collected using an adapted version for people with intellectual disabilities. Resource-use is collected based on secure care records, to estimate intervention and healthcare costs over 19 and 38 weeks. HRQoL and cost data will inform cost-effectiveness based on the incremental cost per quality-adjusted life year over 38 weeks. DISCUSSION: This paper details the planned analyses and discusses recruitment challenges, sample size implications, and effect size assumptions. The plan was developed prior to database lock and unblinding to minimise analytical bias. TRIAL REGISTRATION: ISRCTN, ISRCTN57406593 . Registered on 18/01/2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Condie J, Franklin M, Doorn KA, et al. Statistical and health economic analysis plan for a secure care hospital evaluation of manualised (interpersonal) art-psychotherapy: the SCHEMA randomized controlled trial. Trials. 2025. PMID: 40598493. doi:10.1186/s13063-025-08934-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。